These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 29372353

  • 1. Novel technology of molecular radio-guidance for lymph node dissection in recurrent prostate cancer by PSMA-ligands.
    Rauscher I, Horn T, Eiber M, Gschwend JE, Maurer T.
    World J Urol; 2018 Apr; 36(4):603-608. PubMed ID: 29372353
    [Abstract] [Full Text] [Related]

  • 2. [PSMA-radioguided surgery in localised recurrent prostate cancer].
    Horn T, Rauscher I, Eiber M, Gschwend JE, Maurer T.
    Urologe A; 2017 Nov; 56(11):1417-1423. PubMed ID: 29022058
    [Abstract] [Full Text] [Related]

  • 3. [PSMA-Radioguided Surgery for Salvage Lymphadenectomy in Recurrent Prostate Cancer].
    Rauscher I, Eiber M, Maurer T.
    Aktuelle Urol; 2017 Apr; 48(2):148-152. PubMed ID: 28511221
    [Abstract] [Full Text] [Related]

  • 4. [PSMA-radioguided surgery in localized recurrent prostate cancer : Current and future aspects].
    Rauscher I, Eiber M, Jilg CA, Gschwend JE, Maurer T.
    Urologe A; 2017 Jan; 56(1):18-23. PubMed ID: 27885455
    [Abstract] [Full Text] [Related]

  • 5. Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer.
    Maurer T, Weirich G, Schottelius M, Weineisen M, Frisch B, Okur A, Kübler H, Thalgott M, Navab N, Schwaiger M, Wester HJ, Gschwend JE, Eiber M.
    Eur Urol; 2015 Sep; 68(3):530-4. PubMed ID: 25957851
    [Abstract] [Full Text] [Related]

  • 6. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
    Rauscher I, Maurer T, Beer AJ, Graner FP, Haller B, Weirich G, Doherty A, Gschwend JE, Schwaiger M, Eiber M.
    J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524
    [Abstract] [Full Text] [Related]

  • 7. 99mTechnetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer.
    Maurer T, Robu S, Schottelius M, Schwamborn K, Rauscher I, van den Berg NS, van Leeuwen FWB, Haller B, Horn T, Heck MM, Gschwend JE, Schwaiger M, Wester HJ, Eiber M.
    Eur Urol; 2019 Apr; 75(4):659-666. PubMed ID: 29625755
    [Abstract] [Full Text] [Related]

  • 8. Metastases-yield and Prostate-specific Antigen Kinetics Following Salvage Lymph Node Dissection for Prostate Cancer: A Comparison Between Conventional Surgical Approach and Prostate-specific Membrane Antigen-radioguided Surgery.
    Knipper S, Tilki D, Mansholt J, Berliner C, Bernreuther C, Steuber T, Maurer T, Graefen M.
    Eur Urol Focus; 2019 Jan; 5(1):50-53. PubMed ID: 30292421
    [Abstract] [Full Text] [Related]

  • 9. Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer: a novel technology to detect lymph node metastases.
    Maurer T, Gschwend JE, Eiber M.
    Curr Opin Urol; 2018 Mar; 28(2):191-196. PubMed ID: 29028767
    [Abstract] [Full Text] [Related]

  • 10. Value of 111 In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up.
    Rauscher I, Düwel C, Wirtz M, Schottelius M, Wester HJ, Schwamborn K, Haller B, Schwaiger M, Gschwend JE, Eiber M, Maurer T.
    BJU Int; 2017 Jul; 120(1):40-47. PubMed ID: 27862863
    [Abstract] [Full Text] [Related]

  • 11. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery.
    Knipper S, Mehdi Irai M, Simon R, Koehler D, Rauscher I, Eiber M, van Leeuwen FWB, van Leeuwen P, de Barros H, van der Poel H, Budäus L, Steuber T, Graefen M, Tennstedt P, Heck MM, Horn T, Maurer T.
    Eur Urol; 2023 Jan; 83(1):62-69. PubMed ID: 35718637
    [Abstract] [Full Text] [Related]

  • 12. Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study.
    Gandaglia G, Mazzone E, Stabile A, Pellegrino A, Cucchiara V, Barletta F, Scuderi S, Robesti D, Leni R, Samanes Gajate AM, Picchio M, Gianolli L, Brembilla G, De Cobelli F, van Oosterom MN, van Leeuwen FWB, Montorsi F, Briganti A.
    Eur Urol; 2022 Oct; 82(4):411-418. PubMed ID: 35879127
    [Abstract] [Full Text] [Related]

  • 13. Robot-assisted Prostate-specific Membrane Antigen-radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe: The First Prospective Feasibility Study.
    de Barros HA, van Oosterom MN, Donswijk ML, Hendrikx JJMA, Vis AN, Maurer T, van Leeuwen FWB, van der Poel HG, van Leeuwen PJ.
    Eur Urol; 2022 Jul; 82(1):97-105. PubMed ID: 35339318
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficiency of repeat salvage lymph node dissection for recurrence of prostate cancer using PSMA-radioguided surgery (RGS) after prior salvage lymph node dissection with or without initial RGS support.
    Falkenbach F, Knipper S, Koehler D, Ambrosini F, Steuber T, Graefen M, Budäus L, Eiber M, Lunger L, Lischewski F, Heck MM, Maurer T.
    World J Urol; 2023 Sep; 41(9):2343-2350. PubMed ID: 37515651
    [Abstract] [Full Text] [Related]

  • 15. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Sep; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 16. Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer.
    Horn T, Krönke M, Rauscher I, Haller B, Robu S, Wester HJ, Schottelius M, van Leeuwen FWB, van der Poel HG, Heck M, Gschwend JE, Weber W, Eiber M, Maurer T.
    Eur Urol; 2019 Oct; 76(4):517-523. PubMed ID: 30987843
    [Abstract] [Full Text] [Related]

  • 17. Prostate-specific membrane antigen-radioguided surgery salvage lymph node dissection: experience with fifty oligorecurrent prostate cancer patients.
    Mayr R, Engelmann SU, Yang Y, Haas M, Schmid T, Schnabel MJ, Breyer J, Schmidt D, Eiber M, Denzinger S, Burger M, Hellwig D, Moosbauer J, Grosse J.
    World J Urol; 2024 Aug 12; 42(1):483. PubMed ID: 39133316
    [Abstract] [Full Text] [Related]

  • 18. Clinical performance of 68Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy.
    Kranzbühler B, Nagel H, Becker AS, Müller J, Huellner M, Stolzmann P, Muehlematter U, Guckenberger M, Kaufmann PA, Eberli D, Burger IA.
    Eur J Nucl Med Mol Imaging; 2018 Jan 12; 45(1):20-30. PubMed ID: 29032394
    [Abstract] [Full Text] [Related]

  • 19. A Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging.
    McCarthy M, Francis R, Tang C, Watts J, Campbell A.
    Int J Radiat Oncol Biol Phys; 2019 Jul 15; 104(4):801-808. PubMed ID: 30890448
    [Abstract] [Full Text] [Related]

  • 20. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68 Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer.
    Franklin A, Yaxley WJ, Raveenthiran S, Coughlin G, Gianduzzo T, Kua B, McEwan L, Wong D, Delahunt B, Egevad L, Samaratunga H, Brown N, Parkinson R, Roberts MJ, Yaxley JW.
    BJU Int; 2021 Jan 15; 127(1):71-79. PubMed ID: 32524748
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.